Main Line Health physicians write the book on mitral valve disease
Scott M. Goldman, MD, and William A. Gray, MD, compile the first authoritative reference for cardiac specialists, with key insights and contributions from Lankenau Heart Institute colleagues and leading experts in mitral valve disease.
Wynnewood, PA — Physician experts from Lankenau Heart Institute, part of Main Line Health, have literally written the book on the most common heart valve condition in the United States: mitral valve disease.
Scott M. Goldman, MD, and William A. Gray, MD, two of the country’s leading surgical and interventional experts in mitral valve disease, served as editors of Diagnosis and Treatment of Mitral Valve Disease: A Multidisciplinary Approach. They recruited some of the most influential people advancing the treatment of mitral valve disease from across the United States and Canada to contribute to the volume. The electronic version was released in July, with the hardback due out on October 1. Seventeen colleagues from Lankenau Heart Institute joined experts from the Cleveland Clinic, Penn Medicine, Columbia University Irving Medical Center and other leading institutions in helping to author chapters.
“With all the transformational advances in the treatment of mitral valve disease, Dr. Gray and I felt the time was right to help guide physicians with the most up-to-date information,” said Dr. Goldman, Director, Structural Heart Program, Lankenau Heart Institute, and clinical professor with the Lankenau Institute for Medical Research (LIMR). Dr. Goldman has almost 40 years’ experience with mitral valve repair, is a pioneer in minimally invasive mitral valve surgery and is principal investigator for multiple valve trials.
“We relied on decades of collective experience in the field to assemble a volume of topics that we’ve identified to be the most valuable in managing these patients and delivering the best outcomes,” Dr. Goldman added.
The most common type of mitral valve disease, mitral regurgitation, involves failure of the valve to close completely, allowing blood to leak backward. Severe leakage will result in not enough blood pumping through your heart or the rest of the body, potentially leaving individuals fatigued and short of breath. Heart rhythm problems or heart failure can result if not properly treated.
“In our experience, successful treatment requires a multidisciplinary approach and a super-sub-specialization focus,” said Dr. Gray, System Chief, Division of Cardiovascular Diseases, Main Line Health; co-director, Lankenau Heart Institute; and a LIMR professor. “We sought contributions from an array of specialists, including general and heart failure cardiologists, cardiac surgeons, structural interventional cardiologists, advanced imaging cardiologists, midlevel providers and researchers. We think their perspectives and knowledge will help new mitral valve programs and teams get off to a successful start and allow established programs to advance and thrive.”
The book provides the latest evidence on the development of disease, imaging techniques, and medical, surgical, and transcatheter therapy options for patients with mitral valve disease. It also discusses how to assemble a multidisciplinary team and establish program infrastructure.
Lankenau Heart Institute has a proven track record of offering innovative and successful treatment options for mitral valve disease. The Heart Valve team recently performed its 300th mitral valve repair using the MitraClip™ procedure — a minimally invasive treatment option for those who are too high risk for traditional open heart surgery and select heart patients who remain symptomatic despite guideline-directed medical therapy. Dr. Gray has been involved with MitraClip since its inception almost 20 years ago, including going through Food and Drug Administration studies leading to its approval.
Dr. Gray is principal investigator for more than 50 clinical trials of coronary, endovascular and structural heart interventions.
The book’s other contributing authors from Lankenau Heart Institute are Steven M. Domsky, MD; Douglas B. Esberg, MD; Eric M. Gnall, DO; Katie M. Hawthorne, MD, FACC; Benjamin I. Horn, DO; Manju Bengaluru Jayanna, MD, MS; Gwyneth McNeill, DO; Sehrish Memon, MD; Yinn Shaung Ooi, MD; Michel Pompeu Sá, MD, PhD; Basel Ramlawi, MD, FACS, FACC; K. Marco Rodriguez; Zach Rozenbaum, MD; Serge Sicouri, MD; and Chidinma Tiko-Okoye, MD, MPH.
About Lankenau Heart Institute
Lankenau Heart Institute is Main Line Health’s premier comprehensive cardiovascular program, bringing together cardiologists, cardiovascular surgeons and advanced practice providers across the System’s four acute care hospitals: Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital. Through a coordinated approach, the Institute offers a full continuum of high-quality cardiovascular care — from prevention and diagnostics to clinical trials, advanced treatments and rehabilitation — with a commitment to excellence in outcomes and patient experience.
A nationally recognized leader in innovation and exceptional clinical outcomes, Lankenau Heart Institute is at the forefront of minimally invasive and transcatheter procedures for coronary revascularization, valve repair and replacement, complex aortic surgery and the treatment of advanced heart failure and arrhythmias. Its pioneering work in robotic-assisted and beating-heart techniques and minimally invasive and robotic valve repair continues to shape the future of cardiovascular care. With a robust and influential presence in national clinical trials, its physicians regularly participate in groundbreaking research focused on new therapies, technologies and procedures, primarily through less invasive approaches.
About Main Line Health
Main Line Health® is a not-for-profit health system serving the greater Philadelphia region. The System comprises five hospitals, seven health centers, more than 160 outpatient and physician practice locations, over 14,500 employees and more than 2,200 employed and independent physicians and advanced practice providers.
Founded in 1985, Main Line Health includes four of the region’s most respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as Bryn Mawr Rehab Hospital, one of the nation’s premier facilities for rehabilitative medicine. The System also includes Mirmont Treatment Center, which provides treatment and support for substance use disorders; Main Line Health HomeCare & Hospice; Main Line HealthCare, its employed multispecialty physician network; Lankenau Institute for Medical Research, a leading biomedical research organization; and Main Line Health Centers offering primary and specialty care, lab, radiology and other outpatient services in Broomall, Collegeville, Concordville, Devon, Exton, King of Prussia and Newtown Square.
Main Line Health brings together physicians, advanced practice providers, nurses, researchers and other healthcare professionals across a broad network of inpatient, outpatient, home-based and community-based services. Through this integrated approach, the System delivers high-quality, comprehensive care across the continuum — from primary care and preventive services to complex specialty, surgical, trauma, emergency, rehabilitative, behavioral health, home care and hospice services — with a focus on making care accessible in the communities where people live and work.
Main Line Health also collaborates with leading clinical partners to expand access to specialized care. Through its affiliation with Children's Hospital of Philadelphia, pediatric care is provided at select Main Line Health locations, including neonatal intensive care units at its acute care hospitals and Bryn Mawr Hospital’s Inpatient Pediatric Unit and Emergency Department. Jefferson Health neurosurgeons and neurointerventionalists also provide 24/7 specialized care, including neurointervention and lifesaving stroke care.